Latest

Hodgkin’s Lymphoma Market Poised for Strong Growth Through 2034, Driven by Innovative Therapies and Clinical Advancements | DelveInsight

3 February 2026
DelveInsight’s “Hodgkin’s Lymphoma Market Insights, Epidemiology, and Market Forecast – 2034” report delivers an in-depth understanding of the Hodgkin’s Lymphoma, historical and forecasted epidemiology and the FSGS market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and

Antisense Oligonucleotide Therapeutics Treatment Pipeline Shows Strong Momentum as 70+ Pharma Companies in the Race | DelveInsight

2 February 2026
DelveInsight’s, “Antisense Oligonucleotide Therapeutics Pipeline Insights 2025” report provides comprehensive insights about 70+ companies and 90+ pipeline drugs in the Antisense Oligonucleotide Therapeutics pipeline landscape. It covers the Antisense Oligonucleotide Therapeutics pipeline drug profiles, including clinical and nonclinical stage products. It also covers

Untreated Metastatic or Unresectable Melanoma Clinical Trial Pipeline Expands as 10+ Companies Driving Innovation in the Therapeutics | DelveInsight

2 February 2026
DelveInsight’s, “Untreated Metastatic or Unresectable Melanoma Pipeline Insight, 2025” report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Untreated Metastatic or Unresectable Melanoma pipeline landscape. It covers the Untreated Metastatic or Unresectable Melanoma pipeline drug profiles, including clinical and
IPSEN

FDA Grants Ipsen’s IPN60340 Breakthrough Therapy Designation for First-Line Treatment of Elderly Patients with Acute Myeloid Leukemia

2 February 2026
The Food and Drug Administration (FDA) has awarded Breakthrough Therapy Designation to IPN60340 (ICT01), Ipsen’s investigational anti-BTN3A monoclonal antibody, in combination with venetoclax and azacitidine for first-line treatment of acute myeloid leukemia (AML) in patients ineligible for intensive chemotherapy. This regulatory acceleration

Pneumococcal Infections Clinical Trial Pipeline Expands as 15+ Companies Driving Innovation in the Therapeutics | DelveInsight

29 January 2026
DelveInsight’s, “Pneumococcal Infections Pipeline Insight, 2025” report provides comprehensive insights about 15+ companies and 20+ pipeline drugs in Pneumococcal Infections pipeline landscape. It covers the Pneumococcal Infections pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Pneumococcal Infections
1 21 22 23 24 25 31